Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) has received a consensus rating of “Buy” from the thirteen research ...

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on ...

Needham & Company LLC reiterated their buy rating on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a report ...

Analysts have set 12-month price targets for Avidity Biosciences, revealing an average target of $66.31, a high estimate of ...

Fintel reports that on March 13, 2025, Citigroup initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Buy ...

Avidity Biosciences (RNA) announced del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular dystrophy ...

Fintel reports that on March 12, 2025, BMO Capital initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Outperform ...

In a report released today, Louise Chen from Scotiabank maintained a Buy rating on Avidity Biosciences (RNA – Research Report), with a price ...

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics ...

After some earlier data sparked questions from analysts, Avidity Biosciences has released more data for its RNA-based ...

Avidity Biosciences, Inc. (NASDAQ:RNA) has emerged as a frontrunner in the development of RNA-based therapies, leveraging its proprietary antibody-oligonucleotide conjugate (AOC) platform to ...

SAN DIEGO - Avidity Biosciences, Inc. (NASDAQ:RNA), a biotechnology company with a market capitalization of $3.74 billion, has announced positive topline data from its Phase 1/2 EXPLORE44 trial ...